How much should Gilead Sciences charge for its now-authorized COVID-19 therapy remdesivir? Up to $4,460 per patient, an influential pricing watchdog figures. | While Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at…